Kashiv BioSciences has secured ₹648 crore financing from Union Bank of India to expand its cutting-edge biologics manufacturing facility in Pipan, near Ahmedabad, Gujarat aiming for up to 50,000L capacity in one of India’s largest single-use plants, focused on high-quality biosimilars and specialty pharmaceuticals for global markets.
Glimpse:
Announced December 23, 2025, the funding builds on Kashiv’s earlier $150 million debt raise in April 2025, accelerating monoclonal antibody production to serve U.S., Europe, Canada, and beyond. This state-backed push aligns with Gujarat’s Biotechnology Policy, creating high-value jobs and reinforcing India’s ‘pharmacy of the world’ status amid rising biosimilars demand.
In the heart of Gujarat’s thriving biotech corridor, a quiet revolution is brewing one that could redefine India’s role in the global biologics arena. Kashiv BioSciences, the Indian arm of U.S.-based Kashiv BioSciences LLC, has just clinched a massive ₹648 crore financing deal from Union Bank of India, announced on December 23, 2025. This isn’t standalone capital; it layers atop an earlier $150 million debt facility from GoldenTree Asset Management in April 2025, channeling resources into expanding the company’s flagship single-use manufacturing site in Pipan, just outside Ahmedabad.
What emerges is poised to be one of India’s largest commercial biologics facilities: a state-of-the-art plant scaling to 50,000L capacity, dedicated to monoclonal antibodies (mAbs), biosimilars, and specialty pharmaceuticals. Single-use technology flexible, contamination-resistant bioreactors slashes setup times, boosts efficiency, and aligns with global sustainability trends, making it ideal for high-value, complex molecules that dominate modern therapies for cancer, autoimmune diseases, and beyond.
This expansion isn’t happening in isolation. It dovetails with broader waves sweeping India’s pharma landscape: from recent sovereign cloud pushes for secure health data (like L&T Vyoma’s partnerships) to mobile training labs democratizing surgical skills (Medtronic’s tier-2 outreach) and Odisha’s ₹25,000 crore pharma park ambitions. Kashiv’s move amplifies Gujarat’s biotech surge backed by the Gujarat State Biotechnology Mission (GSBTM) turning Pipan into a hub for innovation-led growth, high-skilled jobs in R&D, quality control, and operations, and export-driven value.
Kashiv already stands out as one of the few fully integrated players with marketed biosimilars, serving regulated markets like the U.S. and Europe. This infusion supercharges that edge, enhancing technical prowess, global competitiveness, and supply resilience amid geopolitical shifts favoring ‘China-plus-one’ strategies. For a nation importing much of its advanced biologics, it’s a stride toward self-reliance echoing parallel efforts in plasma therapeutics (PlasmaGen) and preventive AI platforms (TAKE Solutions).
At full throttle, the Pipan site could pump out therapies reaching millions worldwide, while injecting economic vitality locally: sustainable employment, knowledge transfer, and alignment with Viksit Bharat’s atmanirbhar vision.
“This funding marks a pivotal milestone in expanding biomanufacturing capacity in India accelerating innovation and access to high-quality biologics worldwide.”
By
HB Team
